PDS Biotechnology Co. (NASDAQ:PDSB) Receives Consensus Recommendation of “Buy” from Analysts

Shares of PDS Biotechnology Co. (NASDAQ:PDSB) have been assigned an average rating of “Buy” from the five ratings firms that are currently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $14.25.

Several research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a report on Wednesday, October 2nd. Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st.

PDS Biotechnology Price Performance

Shares of NASDAQ PDSB opened at $3.42 on Wednesday. The firm has a market cap of $125.44 million, a P/E ratio of -2.51 and a beta of 1.90. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45. The company has a 50 day moving average of $3.24 and a 200 day moving average of $3.29. PDS Biotechnology has a twelve month low of $2.53 and a twelve month high of $6.85.

PDS Biotechnology (NASDAQ:PDSB) last issued its earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.08. During the same quarter in the prior year, the company posted ($0.37) earnings per share. As a group, research analysts expect that PDS Biotechnology will post -1.24 EPS for the current fiscal year.

Institutional Trading of PDS Biotechnology

A number of hedge funds have recently modified their holdings of PDSB. Inspirion Wealth Advisors LLC increased its holdings in shares of PDS Biotechnology by 5.5% in the first quarter. Inspirion Wealth Advisors LLC now owns 354,977 shares of the company’s stock valued at $1,406,000 after purchasing an additional 18,383 shares during the last quarter. Kathleen S. Wright Associates Inc. acquired a new stake in shares of PDS Biotechnology in the first quarter valued at approximately $28,000. Vanguard Group Inc. increased its holdings in shares of PDS Biotechnology by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock valued at $6,288,000 after purchasing an additional 82,135 shares during the last quarter. Tempus Wealth Planning LLC acquired a new stake in shares of PDS Biotechnology in the second quarter valued at approximately $55,000. Finally, Ground Swell Capital LLC acquired a new stake in shares of PDS Biotechnology in the second quarter valued at approximately $67,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.